Ilsung Is Co., Ltd. (KRX:003120)

Market Cap	143.91B +36.1%
Revenue (ttm)	64.29B -6.8%
Net Income	1.17B -91.1%
EPS	n/a
Shares Out	6.97M
PE Ratio	123.44
Forward PE	n/a
Dividend	1,200.00 (5.90%)
Ex-Dividend Date	Dec 29, 2025

Volume	2,357
Average Volume	5,083
Open	21,450
Previous Close	20,650
Day's Range	20,350 - 21,450
52-Week Range	16,630 - 31,450
Beta	-0.09
RSI	28.01
Earnings Date	Feb 26, 2026

About Ilsung Is

Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular sys...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1954
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 003120

Financial Performance

In 2025, Ilsung Is's revenue was 64.29 billion, a decrease of -6.85% compared to the previous year's 69.02 billion. Earnings were 1.17 billion, a decrease of -91.10%.